Semax Spray

Research-Documented Benefits

• Cognitive Enhancement — Semax, a synthetic ACTH(4-7) analog, has demonstrated improvements in attention, memory formation, and learning capacity in both animal and human studies.
• BDNF Upregulation — Research shows robust increases in brain-derived neurotrophic factor expression, supporting synaptic plasticity and neuronal survival.
• Neuroprotection — Studies document reduced infarct volume and improved neurological outcomes in rodent models of ischemic stroke.
• Immune Modulation — Demonstrated effects on innate immune gene expression, with potential applications in neurodegenerative disease research.
• Nootropic Activity — Approved in Russia and Ukraine as a nootropic, with documented improvements in cognitive performance under stress and fatigue conditions.

Mechanism of Action

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide based on the ACTH(4-7) fragment, with a C-terminal Pro-Gly-Pro tripeptide extension that stabilizes the molecule against enzymatic degradation.

Primary Pathways

• Neurotrophic Factor Modulation — Upregulates expression of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in cortical and hippocampal neurons, supporting synaptic plasticity and neuronal survival.
• Monoaminergic System — Modulates serotonergic, dopaminergic, and noradrenergic neurotransmission, influencing attention, mood, and cognitive processing speed.
• TrkB Receptor Activation — BDNF upregulation leads to enhanced TrkB receptor signaling, activating PI3K/Akt and MAPK/ERK survival and plasticity pathways.
• Immune Gene Expression — Alters expression of genes involved in innate immunity, vascular function, and inflammatory response in brain tissue.

Semax's mechanism is multifaceted, combining neurotrophic factor enhancement with direct neuromodulatory effects, positioning it as a broad-spectrum nootropic research compound.

Research Protocol Guidelines

All protocols described are for in vitro and in vivo research purposes only. Not for human use.

Preparation

Semax is typically supplied as a nasal spray (0.1% or 1% solution) or lyophilized powder. For nasal spray research, the solution is pre-formulated for intranasal delivery.

Research Dosing (Published Literature)

• Standard research dose: 200-600 mcg/day intranasally, divided into 2-3 administrations
• Neuroprotection studies: Up to 1.2 mg/day in acute neurological research protocols
• In vivo (rodent): 50-100 mcg/kg intranasally or intraperitoneally in cognitive and neuroprotection models
• Duration: 10-14 day treatment cycles in most published protocols

Storage

Store nasal spray solutions at 2-8°C. Lyophilized powder at -20°C. Reconstituted solutions should be used within 14 days. Semax is moderately stable but sensitive to prolonged heat exposure.

Safety & Handling Information

For research use only. Not intended for human or veterinary diagnostic or therapeutic use.

Storage Requirements

• Nasal spray: 2-8°C, use within 14 days of first use
• Lyophilized: -20°C for long-term storage

Clinical Safety Data

Semax has been approved and used clinically in Russia and several CIS countries since the 1990s, providing a substantial safety database. It is well-tolerated at standard doses with minimal reported adverse effects.

Known Considerations

• Despite being an ACTH fragment analog, semax does not affect adrenal steroidogenesis or cortisol levels at standard research doses
• BDNF upregulation may theoretically affect neuroplasticity-dependent experimental paradigms
• No reported dependence, tolerance, or withdrawal effects in published literature
• Nasal route delivers peptide directly to CNS via olfactory pathway; consider this in pharmacokinetic study designs

Handling

Standard laboratory PPE. Nasal spray formulations require aseptic handling to prevent microbial contamination.

Frequently Asked Questions